Avsluttet på dagens høyeste 57.2. Dog noe svakere volum enn tidligere dager
3 Likes
PCIB ser ann muligheten for å kjøre et lite fase 2 studie i Vacc tror jeg. Med eksisterende vaksine der patent har utløpt eller i samarbeid med partner. Dette har de ikke penger til pdd (estimert til ca 50mill NOK), men ikke utenkelig at de
- Vet at det kommer cash i upfront fra AZ og gjør alt av arbeid klart før AZ avtale med upfront foreligger. Da er de klare for å gå ett i fase 2 etter at cash er inne.
- Kjører dette sammen med partner som sponser vaksinen og eller studiet.
- Liten emisjon for å hente inn 50 mill NOK (utenkelig i mine øyne da RELEASE har høyeste pri i følge selskapet selv).
11 Likes
Nesten doblet beholdningen i dag, så nu kan det kun gå en vei…(ikke belåning) håper fruen en dag, får pengene igjen 
18 Likes
Og skulle det ikke gå veien, så får vi håpe at du en dag får igjen fruen… 
5 Likes
Det kan være det samme…mye fisk i havet 
3 Likes
Og mange skjær i sjøen.
6 Likes
De har jo faktisk penger til det, men da har de ikke samtidig penger til å kjøre RELEASE frem til interimavlesning. Og nå har de jo to munner til å mette, burn raten er jo stigende. Den er jo også påvirket av de endringer de gjør i RELEASE studien siden de nå planlegger lokale representanter samt flere siter i Asia… kan ikke huske å ha sett noe om hvilken ekstra kost det blir av, men det er ikke gratis…
Blir det negativt utfall av diskusjonen med AZ og de går for vaksinestudie skal man nok ha noe cash i beredskap for å unngå å bli utvannet.
Vet ikke selv hvordan jeg skal fikse det, men tør ikke låne de pengene… eller så får det bli en litt mindre del av en veldig mye større kake…
1 Like
De har mer enn nok penger til begge deler, går utfra tidlig godkjent release studie, så sparer de mye på det
4 Likes
Ja, det er det det blir, kaka blir større . - Om Pcib fortsetter å bruke pengene forsiktig.
2 Likes
The National Institutes of Health, an agency within the Department of Health and Human Services, has been fast-tracking work with biotech company Moderna to develop a potential vaccine. More than 100 vaccines are in development globally as of April 30, according to the World Health Organization, with at least eight vaccine candidates already in human trials.
Moderna is completing its phase one trial. The company’s potential vaccine contains genetic material called messenger RNA, or mRNA, that was produced in a lab. Last week, Moderna said it would soon begin phase two trials with 600 participants and was finalizing plans for a late-stage trial as early as this summer.
Noen tanker?
7 Likes
https://news.yahoo.com/were-hopeful-pci-biotech-holding-102925241.html
Et lite innlegg om PCIB i Yahoo News, men tolker hele innlegget mer som en “reklame” for et analyseprogram.
De linker til dette i artikkelen:
https://simplywall.st/stocks/no/pharmaceuticals-biotech/ob-pcib/pci-biotech-holding-shares
1 Like
Anbefaler folk å aldri klikke på simplywallstreet- er autogenererte greier.
4 Likes
Jeg søkte, og fikk delvis innsyn/delvis avslag. Det man kan si med sikkerhet er at dette ikke har noe med SARS-CoV-2 å gjøre. Det er et flerårig skattefunnprosjekt (de har altså ikke mottatt penger), som sannsynligvis er fortsettelsen av FimaVACC prosjektet de allerede har gående.
Det ble laget en sluttrapport til prosjektet ‘Fimaporfin - utvikling av nye teknologier for bruk i kreftbehandling, vaksiner og nukleinsyreterapi’, som ble levert inn til Forskningsrådet for noen uker siden. Skule jo gjerne lest den også, men den fikk jeg også tilsendt med nesten bare sorte retusjeringer…
Men av få ting så var denne ikke svart:
Albert Hoffmeister er ny for meg.
https://www.researchgate.net/profile/Albrecht_Hoffmeister
27 Likes
Se der ja. En vaskeekte bukspyttkjertelkreftekspert!
17 Likes
Per snakket i siste podkast om samarbeidsmodeller. Her ser dere hva Pål har fått til i Zurich. Ref til PCIB
Preclinical development of cancer vaccines using photosensitization as adjuvant for stimulation of cytotoxic CD8 T-cells
Dermatologische Klinik, Universitätsspital Zürich, Zürich
CHF 250 000.– | Duration: 1.11. 2014 –31.10. 2016 | KFS 3451-08-2014
Pursuing a dream with photosensitive substances
One of the reasons why vaccines have not had the desired effect on cancer is that the 64 body’s own immune system does not process them optimally. Researchers supported by
the Swiss Cancer Research foundation are using photosensitive substances to intervene in the processes within the immune cells – and are moving one step closer to the vision of vaccination against cancer.
Vaccination that protects the body from cancer is a long-held dream in medicine. The dream became a reality for the first time to a certain extent with the vaccine against certain types of human papillomavirus (HPV) that can cause cervical cancer. But unfortu- nately, there have been no solid successes in prevent- ing other types of cancer. “That is because the immune system can process vaccines in two ways – and cancer vaccines go through the wrong processing”, says Pål Johansen, head of a research team at the Department of Dermatology at the University Hospital Zurich.
Every immune response starts with specialized im- mune cells, called antigen-presenting cells, ingesting the antigen (or vaccine). Depending on whether the antigen is contained in a vesicle within the immune cell or swims freely in the cell fluid, it will be cut up in different ways and displayed on the surface of the antigen-presenting cells. Normally, antigens get into the cell vesicles and from there to a MHC-II-complex, which in the immune system plays a role mainly in the interactions for the production of antibodies. However, if an antigen enters the cell sap, it binds to a MHC-I-complex, which is mainly associated with the maturation of cytotoxic T-cells, the so called killer cells.
In the fight against tumour cells, killer cells have been found to be more effective than antibodies. For this reason, the research project conducted by Johansen and his team aims to deliver the vaccines from the cell vesicle into the cell fluid of the antigen-present- ing cells. In experiments with mice, the researchers combined the antigen with a photosensitizer and ad- ministered it intradermally. When the mice were then exposed to intensive light, the photosensitive sub- stance caused the cell vesicle within the antigen-
presenting cells to burst. As a result, the vaccine en- tered the cell fluid, and the immune response led to enhanced production of killer cells.
“The principle works well in mice”, says Johansen. His team is now planning, in collaboration with an indus- try partner in Norway, first tests with humans. If the encouraging results of the animal experiments are confirmed, medicine will have made a further step toward fulfilling a great dream.
10 Likes
Veldig interessant. Pancreas er jo en av de store uløste kreftmysterier og den mest dødelige. 5 års overlevese for inoperable er vel ennå under 10%. Har vært diskutert før her, men pancreas er nok en veldig aktuelle kandidat for neste indikasjon for fimaChem. Mange likheter med gallegang, unmet medical need, kan belyses etc.
14 Likes
Ja. Jeg tror det er Mye. På gang i Pcib…
Som ikke er i offentligheten.
Har en sterk følelse at de vil bli svært aktive på Corona viruset💥
7 Likes
I 2014 har Herr Hoffmeister skrevet noe om at Pancreatic Cancer and Bil Duct ligner hverandre.
Fimaporfin blitt nevnt, som vi vet nå er i RELEASE (Phase 2/3) study.
Pancreatic Cancer bør være blant de neste satsningsområder.
Palliative Endoscopic Treatment Options in Malignancies of the Biliopancreatic System
Jürgen Feisthammel,* Joachim Mössner, and Albrecht Hoffmeister
*](https://www.ncbi.nlm.nih.gov/pubmed/?term=Hoffmeister%20A[Author]&cauthor=true&cauthor_uid=26288596)
A possible new option in the palliative treatment of biliary tract cancer could be the photochemical internalisation of drugs for cytostatic chemotherapy. This technique is using photosensitizing agents such as disulfonated tetraphenyl chlorin (TPCS2a) intravenously [26,27]. In a second step, light is applied to the bile duct (analog PDT technique as described above). The third step would be the application of cytostatic chemotherapy. Recently, a multicentric phase I/II trial was started for the further study of this new treatment option (PCI A202/12; ClinicalTrials.gov identifier: NCT01900158).
Conclusion
In patients with pancreatic cancer and bile duct cancer there are several disease-specific complications (as described above). In general, most often tumor-derived obstructions of the biliary tract or duodenum are causing complaints. Usually, endoscopic treatment is feasible to at least partially relieve the patientss’ complaints. In early stages of obstructive jaundice, biliary stenting is easier and safer than in the advanced stage. Endoscopic stenting may be technically impossible in advanced stage obstructive jaundice, thus being replaced by a percutaneous drainage (PTCD). This kind of drainage usually impairs quality of life more than endoscopic stenting. Most of the procedures and techniques discussed here are well studied and readily available. However, PDT usually is only available in hospitals of maximal care. Due to the reported cases of lethal hemobilia, the role of RFA still remains unclear. Further studies have to address these safety issues. All the methods described here are palliative means, and none of them allows curing the patient. Despite recent studies showing promising effects of chemotherapy on the survival of patients with pancreatic cancer, treatment remains palliative in the majority of cases [28,29].
16 Likes
5 Likes